- Home
- YJ vs KZIA Comparison
YJ vs KZIA Comparison
Compare YJ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YJ | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 161.5M |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | YJ | KZIA |
|---|---|---|
| Price | $1.40 | $9.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 2.7K | ★ 2.0M |
| Earning Date | 11-25-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,760,127.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $2.86 |
| 52 Week High | $2.67 | $21.00 |
Technical Indicators
Market Signals| Indicator | YJ | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 47.96 |
| Support Level | $1.51 | $9.14 |
| Resistance Level | $1.66 | $17.40 |
| Average True Range (ATR) | 0.05 | 2.51 |
| MACD | 0.00 | -0.37 |
| Stochastic Oscillator | 3.69 | 23.56 |
Price Performance
Historical ComparisonAbout YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.